For years, documentation deficiencies and CAPA gaps dominated 483 observation charts at innovator CMO sites, but that reality has changed. Redica’s analysis of 168 innovator CMO sites shows Facilities & Equipment has surged to become the fastest-growing observation category across the 2022 to 2025 period, distorting what had been a relatively stable distribution of quality citations.

For quality directors at CMOs and CDMOs, and for sponsors evaluating or managing manufacturing partners, the shift is worth understanding in full. Three converging pressures are driving it, and a fourth trend is raising the global stakes. Our new white paper, The New Rules of CMO-Sponsor Collaboration, covers the data in depth.

Three Drivers Behind CMO F&E Observations

• Annex 1 adoption. The EU's revised Annex 1 guideline on sterile manufacturing took effect in August 2023 and represents the most significant update to sterile manufacturing requirements in decades. It imposes comprehensive contamination control strategy requirements and elevated aseptic processing standards that go well beyond what prior guidelines demanded. Facilities being inspected against Annex 1 now face a far more rigorous lens, whether the agency at the door is FDA, MHRA, or EMA.
• The isolator transition. The industry-wide migration from conventional cleanrooms to isolator technology was already underway before COVID, but post-pandemic capacity expansions accelerated it significantly. Many facilities installed new lines or brought renovated capacity back into service on compressed timelines to meet demand. Those facilities are now being inspected, and the qualification gaps, operator training deficiencies, and interface issues that compressed timelines tend to produce are showing up as F&E observations.
• Aging infrastructure. A substantial share of global pharmaceutical manufacturing capacity operates in older buildings with older equipment. These facilities can be kept fully in compliance, but doing so requires intensive maintenance programs and rigorous documentation of condition and lifecycle management. Those are precisely the areas inspectors scrutinize most closely, and facilities that haven't kept pace with new requirements are now generating observations. The frequency of deeper inspections across all three of these categories tracks directly with what’s happening in the market: more new lines, more isolator conversions, and more facilities being held to Annex 1 standards.

Annex 1 Compliance Is a Global CMO Inspection Readiness Issue

The F&E trend connects to a change in how innovator CMO sites are being inspected globally, and understanding that connection shapes how you think about the risk. Redica's data shows that innovator CMO sites are two to three times more likely to be subject to Mutual Recognition Agreement inspections than non-CMO sites. Regulatory cooperation between FDA, EMA, MHRA, and other authorities is increasingly allowing agencies to rely on each other's findings rather than conducting duplicative on-site visits.

For facilities with strong compliance track records, this is a genuine benefit. At established sites with strong compliance histories, MRA frameworks have allowed pre-approval inspections to be mostly waived, reducing the inspection burden for high-performing facilities. The flip side is that a single inspection by one agency now carries more weight across jurisdictions. An MHRA finding on Annex 1 readiness doesn't stay in the UK, but actually informs the FDA's view of that  same facility. Quality gaps that might once have been addressed in one regulatory jurisdiction before becoming visible in another now surface faster and more broadly.

The practical implication for CMOs is that Annex 1 compliance and isolator qualification are global inspection readiness concerns, because the agencies are sharing what they find. A site that treats Annex 1 as primarily a European regulatory obligation is misunderstanding the landscape.

What CMO Inspection Readiness Demands from Facility Investment

The F&E surge sends a clear message to CMO quality leaders: proactive investment in facility condition is now a compliance expense, not just a capital one. An Annex 1 gap assessment still in progress, an isolator qualification compressed to meet a commercial timeline, or maintenance documentation program that hasn't kept pace with aging equipment can all represent an observation waiting to be found.

For sponsors evaluating manufacturing partners, F&E status deserves special attention in qualification audits. Understanding a CMO's Annex 1 compliance timeline, the maturity of its isolator qualification programs, and its approach to aging infrastructure gives a better picture of near-term inspection risk than almost anything else on the audit checklist.

For a more in-depth look at F&E trends, MRA inspections, and the broader shifts reshaping how innovator CMOs are regulated globally, download our white paper: The New Rules of CMO-Sponsor Collaboration: Inspection Trends, Shared Risk, and the Path to Predictive Quality.